Thursday, November 23, 2023
| Welcoming participants |
| 08.15 am-08.45 am (GMT+1)
|
|
|
| Introductory remarks |
| 08.45 am-09.00 am (GMT+1)
|
|
|
| Session 1: Plasticity, genetics, epigenetics |
| 09.00 am-11.55 am (GMT+1)
|
| Chairs: Pauline Spéder, Institut Pasteur, France - Romain Levayer, Institut Pasteur, France |
| 09.00 am |
Ewing sarcoma, a paradigm for cell reprogramming in cancer
Olivier Delattre
Diversity and plasticity of childhood tumors, Institut Curie, Paris, France
|
| 09.25 am |
Leukemic Stem Cells
Andreas Trumpp
Division of Stem Cells and Cancer, German Cancer Research Center (DKFZ) and DKFZ-ZMBH Alliance, Heidelberg, Germany
|
| 09.50 am |
The Splicing-Associated Network PAK1-CLK-SRRM1 is a Critical Vulnerability to Overcome Chemoresistance in Acute Myeloid Leukemia
Camille Vaganay
IRSL, St Louis Hospital, University of Paris-Cité, INSERM UMR 944, Paris, France
|
| 10.05 am |
MYC and MAX drive the reactivation of the genome after mitosis
Inma Gonzalez
Epigenomics, Proliferation and Cell Identity, Institut Pasteur, Paris, France
|
| 10.20 am |
Informal discussion / Coffee break
|
| 10.45 am |
Innate immune self-DNA sensing and cell fate during genotoxic stress
Christian Zierhut
Genome Stability and Innate Immunity Group, The Institute of Cancer Research, London, United Kingdom
|
| 11.10 am |
Systematic mapping of suppression mutations enabling survival of DNA repair-deficient cancer cells
Francois Dossin
Genome Integrity, Immunity and Cancer Unit, Institut Pasteur, Paris, France
|
| 11.25 am |
DNA Replication Licensing Aberrations drive genomic instability and are synthetically lethal with FANCD2 and BRCA2 inactivation
Zoi Lygerou
Department of Gen. Biology, School of Medicine, University of Patras, Rio, Patras, Greece
|
| 11.40 am |
Exploring Oncogenesis with CRISPR to Discover Novel Therapeutic Targets: the example of ROR2 as a new target for ALK+ ALCL
Erika Brunet
Genome Dynamics in the Immune System, Institut Imagine, Montparnasse, France
|
|
| Lunch and Posters session I (Group photo) |
| 11.55 am-2.00 pm (GMT+1)
|
|
|
| Session 2: Competition, heterogeneity, clonality |
| 2.00 pm-4.15 pm (GMT+1)
|
| Chairs: Christian Zierhut, The Institute of Cancer Research, United Kingdom - Erika Brunet, Institut Imagine, France |
| 2.00 pm |
Pro- and anti-oncogenic mutants in normal epithelia
Phil Jones
Epidermal and Oesophageal stem cells, Wellcome Sanger Institute, Hinxton, United Kingdom
|
| 2.25 pm |
P53 activation terminates the fetal-like regenerative state in colitis and promotes a fate switch towards terminally differentiated colonocytes
Kimberly Hartl
Medical Department of Hepatology and Gastroenterology, Charité Universitätsmedizin Berlin, Berlin, Germany Berlin School of Integrative Oncology, Berlin, Germany
|
| 2.40 pm |
Intra tumoral heterogeneity in breast cancers promote cancer cell extrusion by mechanical cell competition
Carine Rosse
UMR144, Institut Curie - centre de recherche, Paris, France Université Paris Cité, CNRS, Institut Jacques Monod, Paris, France
|
| 2.55 pm |
Leveraging cell competition against cancer
Jules Lavalou
School of Cellular and Molecular Medicine, University of Bristol, Bristol, United Kingdom
|
| 3.20 pm |
Insights into "Mechanical Cell Competition": The Independent Roles of Tissue Growth and Junctional Tension
Léo Valon
CDEH, Institut Pasteur, Paris, France UMR 3738, CNRS, Paris, France
|
| 3.35 pm |
Evolution of cancer cells: improving the explanatory power of the clonal evolution model
Lucie Laplane
IHSPT & U1287, CNRS (Univ Paris 1 & Gustave Roussy), Paris, France
|
| 3.50 pm |
Informal discussion / Coffee break
|
|
| Session 3: Motility, biomechanics/physics - Part I |
| 4.15 pm-6.00 pm (GMT+1)
|
| Chairs: Philippe Bousso, Institut Pasteur, France - Isabelle Le Roux, Paris Brain Institute, France |
| 4.15 pm |
Regulation of cell fate and integrity by nuclear mechanotransduction
Sara Wickström
Cell and tissue dynamics, University of Helsinki, Finland / Max Planck Institute for Molecular Biomedicine, Muenster, Germany
|
| 4.40 pm |
Tissue fluidification in pathophysiology
Giorgio Scita
Mechanisms of Tumor Cell Migration, IFOM, University of Milan, Milan, Italy
|
| 5.05 pm |
Cancer cell collective migration
Fanny Jaulin
Collective invasion, Institut Gustave Roussy, Villejuif, France
|
| 5.30 pm |
The Mechanobiology of Microtubules: Understanding How Tumour Cells Survive Confined Spaces
Samantha Stehbens
University of Queensland, St Lucia, Australia
|
| 5.45 pm |
A tug-of-war between cancer stem cells and the host tissue in an invasive tumour of the central nervous system
Pauline Spéder
Structures and Signals in the Neurogenic Niche, Institut Pasteur, Paris, France
|
|
| Cocktail |
| 6.00 pm-8.00 pm (GMT+1)
|
|
|
Friday, November 24, 2023
| Welcoming participants |
| 08.30 am-08.45 am (GMT+1)
|
|
|
| Session 3: Motility, biomechanics/physics - Part II |
| 08.45 am-10.35 am (GMT+1)
|
| Chairs: Erik Sahai, The Francis Crick Institute, United Kingdom - Samantha Stehbens, University of Queensland, Australia |
| 08.45 am |
Cancer-associated fibroblasts actively compress cancer cells modulating their drug resistance and invasion
Danijela Vignjevic
Cell migration and invasion, Institut Curie, Paris, France
|
| 09.10 am |
Intravascular cues shape tumor metastasis
Jacky G Goetz
Tumor biomechanics, Centre de Recherche en Biomédecine de Strasbourg (CRBS), Strasbourg, France
|
| 09.35 am |
The effect of interplay between biophysical matrix properties and remodelling on 3D tumor invasion
Anouk Van Der Net
Bionanoscience, Delft University of Technology, Delft, The Netherlands
|
| 09.50 am |
Role of vimentin in glioblastoma multiforme gene expression
Elvira Infante
Institut Pasteur, Paris, France
|
| 10.05 am |
Informal discussion / Coffee break
|
|
| Session 4: Tumor environment: immune system, nervous system, microbiote - Part I |
| 10.35 am-12.05 pm (GMT+1)
|
| Chairs: Giorgio Scita, Istituto Fondazione di Oncologia Moleculaire, University of Milan, Italy - Elvira Infante, Institut Pasteur, France |
| 10.35 am |
Cell migration and stromal fibroblasts sculpt patterns of cancer invasion, evolution, and therapy resistance
Erik Sahai
Tumor cell biology, The Francis Crick Institute, London, United Kingdom
|
| 11.00 am |
Function-based genomics to combat immunotherapy resistance
Daniel Peeper
Functional oncogenomics and resistance to tumor and immune therapy, The Netherlands Cancer Institute, Amsterdam, The Netherlands
|
| 11.25 am |
Decoding mechanisms of tumor immunotherapies in vivo
Philippe Bousso
Dynamics of immune responses, Institut Pasteur, Paris, France
|
| 11.50 am |
Cellular senescence in malignant cells promotes tumor progression in mouse and patient Glioblastoma
Isabelle Le Roux
Genetic and development of brain tumors, Paris Brain Institute, Paris Cedex13, France
|
|
| Lunch and Poster session II |
| 12.05 pm-2.00 pm (GMT+1)
|
|
|
| Session 4: Tumor environment: immune system, nervous system, microbiote - Part II |
| 2.00 pm-5.20 pm (GMT+1)
|
| Chairs: Jacky G Goetz, Centre de Recherche en Biomédecine de Strasbourg, France - Danijela Vignjevic, Institut Curie, France |
| 2.00 pm |
The dark genome and the immune system
Sebastian Amigorena
Immune responses to cancer, Institut Curie, Paris, France
|
| 2.25 pm |
Cancer Neuroscience of Glioblastoma and Beyond
Frank Winkler
Experimental neurooncology, University Hospital Heidelberg, Heidelberg, Germany
|
| 2.50 pm |
Neutrophils’ influences on metastatic initiation
Ilaria Malanchi
The Francis Crick Institute, United Kingdom
|
| 3.15 pm |
Tunneling nanotubes (TNTs) mediated mitochondria transfer in cancer: A focus on Glioblastoma
Ines Saenz de Santa Maria
Trafic membranaire et pathogenèse, Institut Pasteur, Paris, France
|
| 3.30 pm |
Informal discussion / Coffee break
|
| 4.00 pm |
Microbiome control of host Immunity
Yasmine Belkaid
Director NIAID Microbiome program, Co-Director NIH Center for Human Immunology, Chief Metaorganism Immunology Section, Chief Laboratory of Host Immunity and Microbiome, United States
|
| 4.25 pm |
Melanoma immunotherapy by immune checkpoint blockade activates hematopoietic stem cells and reprograms early hematopoïesis
Pierre Guermonprez
Immunology Department, ''Dendritic cells and adaptive immunity'' unit, Institut Pasteur, Paris, France CNRS UMR3738, ''Developmental Biology and Stem Cells'', Paris, France
|
| 4.50 pm |
New Insights into the Role of Thrombospondin-1 in Glioblastoma Development
Andreas Bikfalvi
Cancer and vascular biology lab (Team 1, INSERM U1312), University of Bordeaux, Pessac, France
|
| 5.05 pm |
Depletion of slow-cycling PDGFRa+ADAM12+ mesenchymal cells promotes antitumor immunity by restricting macrophage efferocytosis
Selene Di Carlo
Stroma, Inflammation & Tissue Repair Unit, Institut Pasteur, Université Paris Cité, INSERM U1224, Paris, France
|
|
| Concluding remarks |
| 5.20 pm-5.30 pm (GMT+1)
|
|
|
